Adjuvant levamisole in the treatment of patients with resectable lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011897:Random Allocation; D012306:Risk; D012882:Skin Tests; D012907:Smoking
D000276:Adjuvants, Immunologic; D007978:Levamisole